Archives for: August 25th, 2017

CorMedix Inc. Announces a Change to its Senior Leadership

Written by Josh Drumm, Ph.D. on August 25, 2017

Bedminster, NJ – August 25, 2017 – CorMedix Inc. (NYSE…

CorMedix, Inc. Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and Prevention of Potentially Life-Threatening Infections in Severe Burns

Written by Josh Drumm, Ph.D. on August 17, 2017

Bedminster, NJ – August 17, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

Written by Josh Drumm, Ph.D. on August 9, 2017

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Directors

Written by Josh Drumm, Ph.D. on August 7, 2017

Current Director Myron Kaplan Elected Chairman of the Board  Bedminster,…

CorMedix Inc. to Report Second Quarter 2017 Financial Results and Provide Business Update

Written by Josh Drumm, Ph.D. on August 4, 2017

Conference Call and Webcast to be held Wednesday, August 9,…

CorMedix Inc. Provides Update on Neutrolin® Ongoing Phase 3 Clinical Trial Following Favorable FDA Correspondence

Written by Josh Drumm, Ph.D. on August 2, 2017

Bedminster, NJ – August 2, 2017 – CorMedix Inc. (NYSE…